Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Role of Large Animal Studies in Cardiac Regenerative Therapy Concise Review of Translational Stem Cell Research

  • Kwon, Sung Uk (Division of Cardiovascular Medicine, Stanford University Medical Center) ;
  • Yeung, Alan C. (Division of Cardiovascular Medicine, Stanford University Medical Center) ;
  • Ikeno, Fumiaki (Division of Cardiovascular Medicine, Stanford University Medical Center)
  • Published : 2013.08.30
⟨ Previous Next ⟩

Abstract

Animal models have long been developed for cardiovascular research. These animal models have been helpful in understanding disease, discovering potential therapeutics, and predicting efficacy. Despite many efforts, however, translational study has been underestimated. Recently, investigations have identified stem cell treatment as a potentially promising cell therapy for regenerative medicine, largely because of the stem cell's ability to differentiate into many functional cell types. Stem cells promise a new era of cell-based therapy for salvaging the heart. However, stem cells have the potential risk of tumor formation. These properties of stem cells are considered a major concern over the efficacy of cell therapy. The translational/preclinical study of stem cells is essential but only at the beginning stages. What types of heart disease are indicated for stem cell therapy, what type of stem cell, what type of animal model, how do we deliver stem cells, and how do we improve heart function? These may be the key issues that the settlement of which would facilitate the transition of stem cell research from bench to bedside. In this review article, we discuss state-of-the-art technology in stem cell therapies for cardiovascular diseases.

Keywords

References

  1. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000;287:1442-6. https://doi.org/10.1126/science.287.5457.1442
  2. Fink DW Jr. FDA regulation of stem cell-based products. Science 2009;324:1662-3. https://doi.org/10.1126/science.1173712
  3. Moos M Jr. Stem-cell-derived products: an FDA update. Trends Pharmacol Sci 2008;29:591-3. https://doi.org/10.1016/j.tips.2008.09.003
  4. Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003;108:2212-8. https://doi.org/10.1161/01.CIR.0000095788.78169.AF
  5. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrowderived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21. https://doi.org/10.1056/NEJMoa060186
  6. Huikuri HV, Kervinen K, Niemela M, et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008;29:2723-32. https://doi.org/10.1093/eurheartj/ehn436
  7. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-209. https://doi.org/10.1056/NEJMoa055706
  8. Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009;30:1313-21. https://doi.org/10.1093/eurheartj/ehp073
  9. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011;306:2110-9. https://doi.org/10.1001/jama.2011.1670
  10. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-57. https://doi.org/10.1016/S0140-6736(11)61590-0
  11. Ang KL, Chin D, Leyva F, et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med 2008;5:663-70. https://doi.org/10.1038/ncpcardio1321
  12. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012;307:1717-26. https://doi.org/10.1001/jama.2012.418
  13. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005;102:11474-9. https://doi.org/10.1073/pnas.0504388102
  14. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010;107:913-22. https://doi.org/10.1161/CIRCRESAHA.110.222703
  15. Ishikawa K, Ladage D, Takewa Y, et al. Development of a preclinical model of ischemic cardiomyopathy in swine. Am J Physiol Heart Circ Physiol 2011;301:H530-7. https://doi.org/10.1152/ajpheart.01103.2010
  16. Mewton N, Rapacchi S, Augeul L, et al. Determination of the myocardial area at risk with pre- versus post-reperfusion imaging techniques in the pig model. Basic Res Cardiol 2011;106:1247-57. https://doi.org/10.1007/s00395-011-0214-8
  17. Schuleri KH, Boyle AJ, Centola M, et al. The adult Gottingen minipig as a model for chronic heart failure after myocardial infarction: focus on cardiovascular imaging and regenerative therapies. Comp Med 2008;58:568-79.
  18. Zhang J, Wilke N, Wang Y, et al. Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31 P-MRS study. Circulation 1996;94:1089-100. https://doi.org/10.1161/01.CIR.94.5.1089
  19. Verdouw PD, van den Doel MA, de Zeeuw S, Duncker DJ. Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res 1998;39:121-35. https://doi.org/10.1016/S0008-6363(98)00069-8
  20. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72. https://doi.org/10.1161/01.CIR.81.4.1161
  21. McCall FC, Telukuntla KS, Karantalis V, et al. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc 2012;7:1479-96. https://doi.org/10.1038/nprot.2012.075
  22. Zhang H, Wang H, Li N, Duan CE, Yang YJ. Cardiac progenitor/stem cells on myocardial infarction or ischemic heart disease: what we have known from current research. Heart Fail Rev 2013. [Epub ahead of print]
  23. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201. https://doi.org/10.1038/nm912
  24. Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 2004;428:660-4. https://doi.org/10.1038/nature02421
  25. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, largescale tissue restoration on the beating heart after myocardial injury. Circulation 2005;112(9 Suppl):I173-7.
  26. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7. https://doi.org/10.1126/science.284.5411.143
  27. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005;102:11474-9. https://doi.org/10.1073/pnas.0504388102
  28. Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005;112(9 Suppl):I150-6.
  29. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006;27:1114-22.
  30. Strauer BE, Brehm M, Zeus T, et al. [Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction]. Dtsch Med Wochenschr 2001;126:932-8. https://doi.org/10.1055/s-2001-16579-1
  31. Dib N, Menasche P, Bartunek JJ, et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv 2010;3:265-75. https://doi.org/10.1016/j.jcin.2009.12.013
  32. Patel AN, Geffner L, Vina RF, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 2005;130:1631-8. https://doi.org/10.1016/j.jtcvs.2005.07.056
  33. Pompilio G, Steinhoff G, Liebold A, et al. Direct minimally invasive intramyocardial injection of bone marrow-derived AC133+ stem cells in patients with refractory ischemia: preliminary results. Thorac Cardiovasc Surg 2008;56:71-6. https://doi.org/10.1055/s-2007-989351
  34. Zhao Q, Sun Y, Xia L, Chen A, Wang Z. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg 2008;86:1833-40. https://doi.org/10.1016/j.athoracsur.2008.08.068
  35. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005;112:1748-55. https://doi.org/10.1161/CIRCULATIONAHA.105.547810
  36. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007;115:3165-72. https://doi.org/10.1161/CIRCULATIONAHA.106.687376
  37. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001;37:1726-32. https://doi.org/10.1016/S0735-1097(01)01200-1
  38. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011;109:923-40. https://doi.org/10.1161/CIRCRESAHA.111.243147
  39. Trachtenberg B, Velazquez DL, Williams AR, et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TACHFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011;161:487-93. https://doi.org/10.1016/j.ahj.2010.11.024
  40. Quevedo HC, Hatzistergos KE, Oskouei BN, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A 2009;106:14022-7. https://doi.org/10.1073/pnas.0903201106
  41. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011;108:792-6. https://doi.org/10.1161/CIRCRESAHA.111.242610
  42. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:208-16.
  43. McCall FC, Telukuntla KS, Karantalis V, et al. Myocardial infarction and intramyocardial injection models in swine. Nat Protoc 2012;7:1479-96. https://doi.org/10.1038/nprot.2012.075
  44. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003;107:2294-302. https://doi.org/10.1161/01.CIR.0000070596.30552.8B
  45. Bubela T, Li MD, Hafez M, Bieber M, Atkins H. Is belief larger than fact: expectations, optimism and reality for translational stem cell research. BMC Med 2012;10:133. https://doi.org/10.1186/1741-7015-10-133

Cited by

  1. Recent Advances of Stem Cell Therapy for Retinitis Pigmentosa vol.15, pp.8, 2013, https://doi.org/10.3390/ijms150814456